Biodegradable artery graft could revolutionize leg bypass surgery
NCT ID NCT07716020
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study tests a new type of bypass graft made from a biodegradable polymer for people with peripheral artery disease who need leg bypass surgery. The graft is designed to restore blood flow and then gradually be replaced by the body's own tissue. The trial will enroll 15 participants across Europe to see if the graft is safe and works as intended.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a biodegradable polymer vascular conduit called the XPAD bypass conduit
- What this could lead to
- If successful, this could provide a new option for bypass surgery that restores blood flow and may reduce complications compared to synthetic grafts.
- What could go wrong
- This is a small, early feasibility study with only 15 participants, so results may not apply broadly. The conduit could fail to stay open or cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 15 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2032
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Participants with peripheral artery occlusion who require elective lower-limb bypass surgery 2. Participant has Rutherford grade 3 or 4 occlusive vascular disease and TASC C or D lesions. 3. At least 18 years of age at screening 4. Suitable anatomy while avoiding joints (assessed by a pre-procedural contrasted CT scan or previous angiogram assessed up to 90 days prior to baseline) 5. Participant has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent 6. Participant has been informed and agrees to pre- and post-procedure follow-up, including follow-up angiography 7. Life expectancy of at least 24 months Exclusion Criteria: 1. Participant requires, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure within 30 days of study procedure. 2. Stroke or myocardial infarction event within 6 weeks of the procedure or evidence of prior massive stroke (Modified Rankin Scale 3 or above) 3. History of acute arterial occlusion requiring an emergent intervention within the last 12 months 4. Severe chronic renal insufficiency (serum creatinine \>2.5 mg/dL) or undergoing hemodialysis 5. Previous renal transplant 6. Uncontrolled arterial hypertension (BP \>200 mmHg) at 2 successive readings 7. Uncontrolled or poorly controlled diabetes 8. Abnormal blood values that could influence participant recovery and or/ graft hemostasis 9. Reduced liver function, defined as: \>2x the upper limit of normal for serum bilirubin, International Normalized Ratio (INR) \>1.5 or prothrombin time (PT) \>18 seconds 10. Any active local or systemic infection 11. Known heparin- induced thrombocytopenia, active bleeding disorder and/or any coagulopathy or thromboembolic disease 12. Allergies to study device (nitinol) or agents/medication, such as contrast agents, aspirin or NOACs, that can't be controlled medically 13. Previous enrolment in this study 14. Participant is participating in another study 15. Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives 16. Any other condition which, in the judgement of the investigator would preclude adequate evaluation for the safety and performance of the study conduit Intra-operative exclusion criteria: 1\. Unsuitable anatomy to implant the XPAD conduit (e.g. target vessel diameter smaller than anticipated; severe calcification)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Peripheral arterial disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smartwatch-Coached walking at home put to the test for leg artery disease
- Could pressing instead of plugging let patients walk sooner after leg artery procedures?
- Which artery plug works best? trial pits proglide against femoseal
- Can artery clearing for blocked legs be done without an overnight stay?
- AI plus ultrasound could catch heart and lung decline before it turns critical
- A window into living tissue: new sensor may spot dangerous oxygen drops during surgery